Pacira BioSciences, Inc. (PCRX): Cash & Equivalents
$158.54M
As of 2025-12-31
$205.88M
As of 2026-06-30
+15.0%
3-year compound annual growth
+9.7%
5-year compound annual growth
+10.8%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $158.54M | -42.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $276.77M | +80.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $153.30M | +47.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $104.14M | -82.2% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $585.58M | +485.8% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $99.96M | +27.8% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $78.23M | -41.0% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $132.53M | +144.8% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $54.13M | +50.6% | 2020-02-21, Balance as of period end |
| 2016-12-31 | $35.94M | -36.9% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $56.98M | +51.9% | 2018-02-28, Balance as of period end |
| 2014-12-31 | $37.52M | +199.8% | 2017-03-01, Balance as of period end |
| 2013-12-31 | $12.52M | +23.6% | 2016-02-25, Balance as of period end |
| 2012-12-31 | $10.13M | -78.1% | 2015-02-24, Balance as of period end |
| 2011-12-31 | $46.17M | +76.7% | 2014-02-25, Balance as of period end |
| 2010-12-31 | $26.13M | +269.3% | 2013-03-07, Balance as of period end |
| 2009-12-31 | $7.08M | n/a | 2012-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $128.45M | +85.3% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $205.40M | +106.4% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $231.25M | +227.7% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $421.00M | +142.0% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $322.93M | +2.4% |
Compare PCRX, AMPH, SUPN, EBS side by side · Screen every company in Pharmaceutical Preparations ↗